Packaging Coordinators, Inc.

PCI Pharma Services, a global CDMO specializing in biotherapies, received strategic investment co-led by Bain Capital and existing investor Kohlberg, with support from Mubadala Investment Company.

PCI Pharma Services is launching a new 50,000-square-foot sterile fill-finish facility in Bedford, NH, expected to reach full GMP production by summer 2025.

PCI Pharma Services is acquiring Ajinomoto Althea, a US-based sterile fill-finish CDMO, with the transaction expected to close in May 2025.

• Lyophilized drug approvals have seen a 15% average annual increase over the past decade, with 336 approvals between 2012-2022 representing 59% of all such approvals since 1954. • In 2022, the FDA approved 32 lyophilized drug products, with oncology and infectious disease treatments accounting for 82% of these approvals. • PCI Pharma Services is investing $100 million in expanding its lyophilization capabilities, including automated twin lyophilizers and an Annex 1 compliant isolator vial filling line in Bedford, New Hampshire.